ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Live & Inactivated Ruminants Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-1Z17317
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Live Inactivated Ruminants Vaccine Market Research Report 2024
BUY CHAPTERS

Global Live & Inactivated Ruminants Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-1Z17317
Report
November 2025
Pages:154
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Boehringer Ingelheim International GmbH
Zoetis Inc
Merck& Co. Inc
Bimeda
Elanco Animal Health Inc.
Virbac
Ceva Sante Animale
Indian Immunologicals Ltd
Vaxxinova International BV (EW Group)
Jinyu Bio-Technology
CNBG
China Animal Husbandry Industry Co., Ltd
CZ Vaccines S.A.U.
Merck& Co. Inc

Live & Inactivated Ruminants Vaccine Market

The global Live & Inactivated Ruminants Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Live and inactivated vaccines are both important tools in preventing diseases in ruminant animals such as cattle, sheep, and goats. Live vaccines contain weakened forms of the pathogen, stimulating a strong immune response similar to natural infection without causing disease. These vaccines often provide rapid and long-lasting immunity with fewer doses required but may pose a risk to immunocompromised animals. In contrast, inactivated vaccines contain killed pathogens that cannot cause disease but still trigger an immune response. While generally safer for all animals, they may require multiple doses or boosters for effective immunity. The choice between live and inactivated vaccines depends on factors like disease prevalence, animal health status, and desired duration of immunity, with veterinarians tailoring vaccination programs to optimize herd health and productivity. Regular vaccination plays a critical role in disease prevention and control within ruminant populations.
From a downstream perspective, Cattle accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Live & Inactivated Ruminants Vaccine leading manufacturers including Boehringer Ingelheim International GmbH, Zoetis, Inc., Merck & Co., Inc., Bimeda, Inc., Elanco Animal Health, Inc., Virbac, Ceva Sante Animale, CZ Vaccines S.A.U., Indian Immunologicals Ltd., Vaxxinova International BV (EW Group), etc., dominate supply; the top five capture approximately % of global revenue, with Boehringer Ingelheim International GmbH leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Live & Inactivated Ruminants Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Live & Inactivated Ruminants Vaccine Market Report

Report Metric Details
Report Name Live & Inactivated Ruminants Vaccine Market
Segment by Type
  • Modified/ Attenuated Live Vaccines
  • Inactivated (Killed) Vaccines
  • Others
Segment by Application
  • Cattle
  • Sheep & Goats
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Boehringer Ingelheim International GmbH, Zoetis, Inc., Merck & Co., Inc., Bimeda, Inc., Elanco Animal Health, Inc., Virbac, Ceva Sante Animale, CZ Vaccines S.A.U., Indian Immunologicals Ltd., Vaxxinova International BV (EW Group), Jinyu Bio-Technology, CNBG, China Animal Husbandry Industry Co., Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Live & Inactivated Ruminants Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Live & Inactivated Ruminants Vaccine Market report?

Ans: The main players in the Live & Inactivated Ruminants Vaccine Market are Boehringer Ingelheim International GmbH, Zoetis, Inc., Merck & Co., Inc., Bimeda, Inc., Elanco Animal Health, Inc., Virbac, Ceva Sante Animale, CZ Vaccines S.A.U., Indian Immunologicals Ltd., Vaxxinova International BV (EW Group), Jinyu Bio-Technology, CNBG, China Animal Husbandry Industry Co., Ltd.

What are the Application segmentation covered in the Live & Inactivated Ruminants Vaccine Market report?

Ans: The Applications covered in the Live & Inactivated Ruminants Vaccine Market report are Cattle, Sheep & Goats

What are the Type segmentation covered in the Live & Inactivated Ruminants Vaccine Market report?

Ans: The Types covered in the Live & Inactivated Ruminants Vaccine Market report are Modified/ Attenuated Live Vaccines, Inactivated (Killed) Vaccines, Others

1 Study Coverage
1.1 Introduction to Live & Inactivated Ruminants Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Live & Inactivated Ruminants Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Modified/ Attenuated Live Vaccines
1.2.3 Inactivated (Killed) Vaccines
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Live & Inactivated Ruminants Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cattle
1.3.3 Sheep & Goats
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Live & Inactivated Ruminants Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Live & Inactivated Ruminants Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Live & Inactivated Ruminants Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Live & Inactivated Ruminants Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Live & Inactivated Ruminants Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Live & Inactivated Ruminants Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Modified/ Attenuated Live Vaccines Market Size by Manufacturers
3.5.2 Inactivated (Killed) Vaccines Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Live & Inactivated Ruminants Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Live & Inactivated Ruminants Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Live & Inactivated Ruminants Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Live & Inactivated Ruminants Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Live & Inactivated Ruminants Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Live & Inactivated Ruminants Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America Live & Inactivated Ruminants Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Live & Inactivated Ruminants Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Live & Inactivated Ruminants Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe Live & Inactivated Ruminants Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Live & Inactivated Ruminants Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Live & Inactivated Ruminants Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Live & Inactivated Ruminants Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Live & Inactivated Ruminants Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Live & Inactivated Ruminants Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America Live & Inactivated Ruminants Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Live & Inactivated Ruminants Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Live & Inactivated Ruminants Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Live & Inactivated Ruminants Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Live & Inactivated Ruminants Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Boehringer Ingelheim International GmbH
11.1.1 Boehringer Ingelheim International GmbH Corporation Information
11.1.2 Boehringer Ingelheim International GmbH Business Overview
11.1.3 Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.1.4 Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine Sales by Product in 2024
11.1.6 Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine Sales by Application in 2024
11.1.7 Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine Sales by Geographic Area in 2024
11.1.8 Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine SWOT Analysis
11.1.9 Boehringer Ingelheim International GmbH Recent Developments
11.2 Zoetis, Inc.
11.2.1 Zoetis, Inc. Corporation Information
11.2.2 Zoetis, Inc. Business Overview
11.2.3 Zoetis, Inc. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.2.4 Zoetis, Inc. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Zoetis, Inc. Live & Inactivated Ruminants Vaccine Sales by Product in 2024
11.2.6 Zoetis, Inc. Live & Inactivated Ruminants Vaccine Sales by Application in 2024
11.2.7 Zoetis, Inc. Live & Inactivated Ruminants Vaccine Sales by Geographic Area in 2024
11.2.8 Zoetis, Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
11.2.9 Zoetis, Inc. Recent Developments
11.3 Merck & Co., Inc.
11.3.1 Merck & Co., Inc. Corporation Information
11.3.2 Merck & Co., Inc. Business Overview
11.3.3 Merck & Co., Inc. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.3.4 Merck & Co., Inc. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Merck & Co., Inc. Live & Inactivated Ruminants Vaccine Sales by Product in 2024
11.3.6 Merck & Co., Inc. Live & Inactivated Ruminants Vaccine Sales by Application in 2024
11.3.7 Merck & Co., Inc. Live & Inactivated Ruminants Vaccine Sales by Geographic Area in 2024
11.3.8 Merck & Co., Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
11.3.9 Merck & Co., Inc. Recent Developments
11.4 Bimeda, Inc.
11.4.1 Bimeda, Inc. Corporation Information
11.4.2 Bimeda, Inc. Business Overview
11.4.3 Bimeda, Inc. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.4.4 Bimeda, Inc. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Bimeda, Inc. Live & Inactivated Ruminants Vaccine Sales by Product in 2024
11.4.6 Bimeda, Inc. Live & Inactivated Ruminants Vaccine Sales by Application in 2024
11.4.7 Bimeda, Inc. Live & Inactivated Ruminants Vaccine Sales by Geographic Area in 2024
11.4.8 Bimeda, Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
11.4.9 Bimeda, Inc. Recent Developments
11.5 Elanco Animal Health, Inc.
11.5.1 Elanco Animal Health, Inc. Corporation Information
11.5.2 Elanco Animal Health, Inc. Business Overview
11.5.3 Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.5.4 Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine Sales by Product in 2024
11.5.6 Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine Sales by Application in 2024
11.5.7 Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine Sales by Geographic Area in 2024
11.5.8 Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
11.5.9 Elanco Animal Health, Inc. Recent Developments
11.6 Virbac
11.6.1 Virbac Corporation Information
11.6.2 Virbac Business Overview
11.6.3 Virbac Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.6.4 Virbac Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Virbac Recent Developments
11.7 Ceva Sante Animale
11.7.1 Ceva Sante Animale Corporation Information
11.7.2 Ceva Sante Animale Business Overview
11.7.3 Ceva Sante Animale Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.7.4 Ceva Sante Animale Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Ceva Sante Animale Recent Developments
11.8 CZ Vaccines S.A.U.
11.8.1 CZ Vaccines S.A.U. Corporation Information
11.8.2 CZ Vaccines S.A.U. Business Overview
11.8.3 CZ Vaccines S.A.U. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.8.4 CZ Vaccines S.A.U. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 CZ Vaccines S.A.U. Recent Developments
11.9 Indian Immunologicals Ltd.
11.9.1 Indian Immunologicals Ltd. Corporation Information
11.9.2 Indian Immunologicals Ltd. Business Overview
11.9.3 Indian Immunologicals Ltd. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.9.4 Indian Immunologicals Ltd. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Indian Immunologicals Ltd. Recent Developments
11.10 Vaxxinova International BV (EW Group)
11.10.1 Vaxxinova International BV (EW Group) Corporation Information
11.10.2 Vaxxinova International BV (EW Group) Business Overview
11.10.3 Vaxxinova International BV (EW Group) Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.10.4 Vaxxinova International BV (EW Group) Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Vaxxinova International BV (EW Group) Recent Developments
11.11 Jinyu Bio-Technology
11.11.1 Jinyu Bio-Technology Corporation Information
11.11.2 Jinyu Bio-Technology Business Overview
11.11.3 Jinyu Bio-Technology Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.11.4 Jinyu Bio-Technology Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Jinyu Bio-Technology Recent Developments
11.12 CNBG
11.12.1 CNBG Corporation Information
11.12.2 CNBG Business Overview
11.12.3 CNBG Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.12.4 CNBG Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 CNBG Recent Developments
11.13 China Animal Husbandry Industry Co., Ltd.
11.13.1 China Animal Husbandry Industry Co., Ltd. Corporation Information
11.13.2 China Animal Husbandry Industry Co., Ltd. Business Overview
11.13.3 China Animal Husbandry Industry Co., Ltd. Live & Inactivated Ruminants Vaccine Product Models, Descriptions and Specifications
11.13.4 China Animal Husbandry Industry Co., Ltd. Live & Inactivated Ruminants Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 China Animal Husbandry Industry Co., Ltd. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Live & Inactivated Ruminants Vaccine Industry Chain
12.2 Live & Inactivated Ruminants Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Live & Inactivated Ruminants Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Live & Inactivated Ruminants Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Live & Inactivated Ruminants Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Live & Inactivated Ruminants Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Boehringer Ingelheim International GmbH
Zoetis Inc
Merck& Co. Inc
Bimeda
Elanco Animal Health Inc.
Virbac
Ceva Sante Animale
Indian Immunologicals Ltd
Vaxxinova International BV (EW Group)
Jinyu Bio-Technology
CNBG
China Animal Husbandry Industry Co., Ltd
CZ Vaccines S.A.U.
Merck& Co. Inc
List of Tables
 Table 1. Global Live & Inactivated Ruminants Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Live & Inactivated Ruminants Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Live & Inactivated Ruminants Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Live & Inactivated Ruminants Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Live & Inactivated Ruminants Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Live & Inactivated Ruminants Vaccine Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Live & Inactivated Ruminants Vaccine Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Live & Inactivated Ruminants Vaccine Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Live & Inactivated Ruminants Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global Live & Inactivated Ruminants Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Live & Inactivated Ruminants Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Live & Inactivated Ruminants Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live & Inactivated Ruminants Vaccine as of 2024)
 Table 16. Global Live & Inactivated Ruminants Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Live & Inactivated Ruminants Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Live & Inactivated Ruminants Vaccine Manufacturing Base and Headquarters
 Table 19. Global Live & Inactivated Ruminants Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Live & Inactivated Ruminants Vaccine Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Live & Inactivated Ruminants Vaccine Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Live & Inactivated Ruminants Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Live & Inactivated Ruminants Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Live & Inactivated Ruminants Vaccine ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Live & Inactivated Ruminants Vaccine Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Live & Inactivated Ruminants Vaccine Sales by Application (2026-2031) & (K Dose)
 Table 30. Live & Inactivated Ruminants Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Live & Inactivated Ruminants Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Live & Inactivated Ruminants Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Live & Inactivated Ruminants Vaccine ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Live & Inactivated Ruminants Vaccine Growth Accelerators and Market Barriers
 Table 37. North America Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Live & Inactivated Ruminants Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Live & Inactivated Ruminants Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Live & Inactivated Ruminants Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Live & Inactivated Ruminants Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Live & Inactivated Ruminants Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Live & Inactivated Ruminants Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Live & Inactivated Ruminants Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Live & Inactivated Ruminants Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Boehringer Ingelheim International GmbH Corporation Information
 Table 51. Boehringer Ingelheim International GmbH Description and Major Businesses
 Table 52. Boehringer Ingelheim International GmbH Product Models, Descriptions and Specifications
 Table 53. Boehringer Ingelheim International GmbH Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Boehringer Ingelheim International GmbH Sales Value Proportion by Product in 2024
 Table 55. Boehringer Ingelheim International GmbH Sales Value Proportion by Application in 2024
 Table 56. Boehringer Ingelheim International GmbH Sales Value Proportion by Geographic Area in 2024
 Table 57. Boehringer Ingelheim International GmbH Live & Inactivated Ruminants Vaccine SWOT Analysis
 Table 58. Boehringer Ingelheim International GmbH Recent Developments
 Table 59. Zoetis, Inc. Corporation Information
 Table 60. Zoetis, Inc. Description and Major Businesses
 Table 61. Zoetis, Inc. Product Models, Descriptions and Specifications
 Table 62. Zoetis, Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Zoetis, Inc. Sales Value Proportion by Product in 2024
 Table 64. Zoetis, Inc. Sales Value Proportion by Application in 2024
 Table 65. Zoetis, Inc. Sales Value Proportion by Geographic Area in 2024
 Table 66. Zoetis, Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
 Table 67. Zoetis, Inc. Recent Developments
 Table 68. Merck & Co., Inc. Corporation Information
 Table 69. Merck & Co., Inc. Description and Major Businesses
 Table 70. Merck & Co., Inc. Product Models, Descriptions and Specifications
 Table 71. Merck & Co., Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Merck & Co., Inc. Sales Value Proportion by Product in 2024
 Table 73. Merck & Co., Inc. Sales Value Proportion by Application in 2024
 Table 74. Merck & Co., Inc. Sales Value Proportion by Geographic Area in 2024
 Table 75. Merck & Co., Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
 Table 76. Merck & Co., Inc. Recent Developments
 Table 77. Bimeda, Inc. Corporation Information
 Table 78. Bimeda, Inc. Description and Major Businesses
 Table 79. Bimeda, Inc. Product Models, Descriptions and Specifications
 Table 80. Bimeda, Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Bimeda, Inc. Sales Value Proportion by Product in 2024
 Table 82. Bimeda, Inc. Sales Value Proportion by Application in 2024
 Table 83. Bimeda, Inc. Sales Value Proportion by Geographic Area in 2024
 Table 84. Bimeda, Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
 Table 85. Bimeda, Inc. Recent Developments
 Table 86. Elanco Animal Health, Inc. Corporation Information
 Table 87. Elanco Animal Health, Inc. Description and Major Businesses
 Table 88. Elanco Animal Health, Inc. Product Models, Descriptions and Specifications
 Table 89. Elanco Animal Health, Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 90. Elanco Animal Health, Inc. Sales Value Proportion by Product in 2024
 Table 91. Elanco Animal Health, Inc. Sales Value Proportion by Application in 2024
 Table 92. Elanco Animal Health, Inc. Sales Value Proportion by Geographic Area in 2024
 Table 93. Elanco Animal Health, Inc. Live & Inactivated Ruminants Vaccine SWOT Analysis
 Table 94. Elanco Animal Health, Inc. Recent Developments
 Table 95. Virbac Corporation Information
 Table 96. Virbac Description and Major Businesses
 Table 97. Virbac Product Models, Descriptions and Specifications
 Table 98. Virbac Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 99. Virbac Recent Developments
 Table 100. Ceva Sante Animale Corporation Information
 Table 101. Ceva Sante Animale Description and Major Businesses
 Table 102. Ceva Sante Animale Product Models, Descriptions and Specifications
 Table 103. Ceva Sante Animale Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 104. Ceva Sante Animale Recent Developments
 Table 105. CZ Vaccines S.A.U. Corporation Information
 Table 106. CZ Vaccines S.A.U. Description and Major Businesses
 Table 107. CZ Vaccines S.A.U. Product Models, Descriptions and Specifications
 Table 108. CZ Vaccines S.A.U. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 109. CZ Vaccines S.A.U. Recent Developments
 Table 110. Indian Immunologicals Ltd. Corporation Information
 Table 111. Indian Immunologicals Ltd. Description and Major Businesses
 Table 112. Indian Immunologicals Ltd. Product Models, Descriptions and Specifications
 Table 113. Indian Immunologicals Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 114. Indian Immunologicals Ltd. Recent Developments
 Table 115. Vaxxinova International BV (EW Group) Corporation Information
 Table 116. Vaxxinova International BV (EW Group) Description and Major Businesses
 Table 117. Vaxxinova International BV (EW Group) Product Models, Descriptions and Specifications
 Table 118. Vaxxinova International BV (EW Group) Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 119. Vaxxinova International BV (EW Group) Recent Developments
 Table 120. Jinyu Bio-Technology Corporation Information
 Table 121. Jinyu Bio-Technology Description and Major Businesses
 Table 122. Jinyu Bio-Technology Product Models, Descriptions and Specifications
 Table 123. Jinyu Bio-Technology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 124. Jinyu Bio-Technology Recent Developments
 Table 125. CNBG Corporation Information
 Table 126. CNBG Description and Major Businesses
 Table 127. CNBG Product Models, Descriptions and Specifications
 Table 128. CNBG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 129. CNBG Recent Developments
 Table 130. China Animal Husbandry Industry Co., Ltd. Corporation Information
 Table 131. China Animal Husbandry Industry Co., Ltd. Description and Major Businesses
 Table 132. China Animal Husbandry Industry Co., Ltd. Product Models, Descriptions and Specifications
 Table 133. China Animal Husbandry Industry Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 134. China Animal Husbandry Industry Co., Ltd. Recent Developments
 Table 135. Key Raw Materials Distribution
 Table 136. Raw Materials Key Suppliers
 Table 137. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 138. Milestones in Production Technology Evolution
 Table 139. Distributors List
 Table 140. Market Trends and Market Evolution
 Table 141. Market Drivers and Opportunities
 Table 142. Market Challenges, Risks, and Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources


List of Figures
 Figure 1. Live & Inactivated Ruminants Vaccine Product Picture
 Figure 2. Global Live & Inactivated Ruminants Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Modified/ Attenuated Live Vaccines Product Picture
 Figure 4. Inactivated (Killed) Vaccines Product Picture
 Figure 5. Others Product Picture
 Figure 6. Global Live & Inactivated Ruminants Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Cattle
 Figure 8. Sheep & Goats
 Figure 9. Live & Inactivated Ruminants Vaccine Report Years Considered
 Figure 10. Global Live & Inactivated Ruminants Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Live & Inactivated Ruminants Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Live & Inactivated Ruminants Vaccine Revenue Market Share by Region (2020-2031)
 Figure 14. Global Live & Inactivated Ruminants Vaccine Sales (2020-2031) & (K Dose)
 Figure 15. Global Live & Inactivated Ruminants Vaccine Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 16. Global Live & Inactivated Ruminants Vaccine Sales Market Share by Region (2020-2031)
 Figure 17. Top 5 and Top 10 Manufacturers Live & Inactivated Ruminants Vaccine Sales Volume Market Share in 2024
 Figure 18. Global Live & Inactivated Ruminants Vaccine Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. Modified/ Attenuated Live Vaccines Revenue Market Share by Manufacturer in 2024
 Figure 21. Inactivated (Killed) Vaccines Revenue Market Share by Manufacturer in 2024
 Figure 22. Others Revenue Market Share by Manufacturer in 2024
 Figure 23. Global Live & Inactivated Ruminants Vaccine Sales Market Share by Type (2020-2031)
 Figure 24. Global Live & Inactivated Ruminants Vaccine Revenue Market Share by Type (2020-2031)
 Figure 25. Global Live & Inactivated Ruminants Vaccine Sales Market Share by Application (2020-2031)
 Figure 26. Global Live & Inactivated Ruminants Vaccine Revenue Market Share by Application (2020-2031)
 Figure 27. North America Live & Inactivated Ruminants Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 28. North America Live & Inactivated Ruminants Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. North America Top 5 Manufacturers Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) in 2024
 Figure 30. North America Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Type (2020- 2031)
 Figure 31. North America Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 32. North America Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 33. North America Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 34. US Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 35. Canada Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 36. Mexico Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 37. Europe Live & Inactivated Ruminants Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 38. Europe Live & Inactivated Ruminants Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Europe Top 5 Manufacturers Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) in 2024
 Figure 40. Europe Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Type (2020-2031)
 Figure 41. Europe Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Europe Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 43. Europe Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Germany Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 45. France Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. U.K. Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. Italy Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 48. Russia Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Live & Inactivated Ruminants Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 50. Asia-Pacific Live & Inactivated Ruminants Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 51. Asia-Pacific Top 8 Manufacturers Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) in 2024
 Figure 52. Asia-Pacific Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Type (2020- 2031)
 Figure 53. Asia-Pacific Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 54. Asia-Pacific Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 55. Asia-Pacific Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Indonesia Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 57. Japan Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. South Korea Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. China Taiwan Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 60. India Live & Inactivated Ruminants Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 61. Central and South America Live & Inactivated Ruminants Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 62. Central and South America Live & Inactivated Ruminants Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Central and South America Top 5 Manufacturers Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) in 2024
 Figure 64. Central and South America Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Type (2021-2031)
 Figure 65. Central and South America Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Central and South America Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 67. Central and South America Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 68. Brazil Live & Inactivated Ruminants Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 69. Argentina Live & Inactivated Ruminants Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 70. Middle East, and Africa Live & Inactivated Ruminants Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 71. Middle East and Africa Live & Inactivated Ruminants Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 72. Middle East and Africa Top 5 Manufacturers Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) in 2024
 Figure 73. Middle East and Africa Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Type (2021-2031)
 Figure 74. South America Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 75. Middle East and Africa Live & Inactivated Ruminants Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 76. Middle East and Africa Live & Inactivated Ruminants Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 77. GCC Countries Live & Inactivated Ruminants Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 78. Turkey Live & Inactivated Ruminants Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. Egypt Live & Inactivated Ruminants Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 80. South Africa Live & Inactivated Ruminants Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 81. Live & Inactivated Ruminants Vaccine Industry Chain Mapping
 Figure 82. Regional Live & Inactivated Ruminants Vaccine Manufacturing Base Distribution (%)
 Figure 83. Global Live & Inactivated Ruminants Vaccine Production Market Share by Region (2020-2031)
 Figure 84. Live & Inactivated Ruminants Vaccine Production Process
 Figure 85. Regional Live & Inactivated Ruminants Vaccine Production Cost Structure
 Figure 86. Channels of Distribution (Direct Vs Distribution)
 Figure 87. Bottom-up and Top-down Approaches for This Report
 Figure 88. Data Triangulation
 Figure 89. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Small Ruminant Vaccine Market Research Report 2024
Ruminant Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Livestock Vaccines Market Research Report 2025
Global Livestock Animal Vaccination Market Research Report 2025
Sheep and Goat Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cattle and Sheep Routine Vaccine Market Research Report 2024
Global Livestock Animal Vaccines Market Research Report 2024
Veterinary Vaccine Market
Global Veterinary Biological Vaccines Market Research Report 2025
Vaccines for Livestock Farming Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cattle and Sheep Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Poultry Killed Vaccines Market Research Report 2025
Inactivated Vaccine Market
Farm Animal Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Livestock mRNA Vaccines Market Research Report 2025
Global Veterinary Vaccination Market Research Report 2025
Global Pet Inactivated Vaccine Market Research Report 2025
Global Poultry Live Vaccines Market Research Report 2025
Global Vaccines For Cattle And Sheep Market Research Report 2024
Global Poultry Live Attenuated Vaccine Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions